Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05853887 · ClinicalTrials.gov registry record · NA
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
A NA study of Non Small Cell Lung Cancer Metastatic and Newly Diagnosed NSCLC, sponsored by Charu Aggarwal.
- Active
- Registry status
- NA
- Development phase
- 260
- Enrollment target
- 6
- Study locations
NCT05853887 is a NA study of Non Small Cell Lung Cancer Metastatic and Newly Diagnosed NSCLC that is active but no longer recruiting, run by Charu Aggarwal. The registered enrollment target is 260 participants, below the 420-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (38% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT05853887, a NA study of Non Small Cell Lung Cancer Metastatic and Newly Diagnosed NSCLC, is active but no longer recruiting, sponsored by Charu Aggarwal.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 260 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.
Conditions Studied
Interventions
- BEHAVIORAL iNUDGE
Study Locations (6)
New Jersey
- Penn Medicine Cherry Hill - Cherry Hill
- Penn Medicine Princeton Health - Plainsboro
- Penn Medicine Washington Township - Sewell
- Penn Medicine Voorhees - Voorhees Township
Pennsylvania
- Penn Medicine Lancaster General Health - Lancaster
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05853887
The ClinicalTrials.gov registry entry for NCT05853887 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 420-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (38% lower). The listed sponsor is Charu Aggarwal, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non Small Cell Lung Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which iNUDGE is the first listed.
NCT05853887 reports 6 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05853887 about?
NCT05853887 is a clinical study titled "Liquid Biopsy Based NGS in Newly Diagnosed NSCLC". This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available ...
What is the current status of trial NCT05853887?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 260 participants. The study started on 2023-06-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05853887 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung.
What interventions are being tested in trial NCT05853887?
The interventions under investigation include: iNUDGE (BEHAVIORAL).
Who is sponsoring clinical trial NCT05853887?
This trial is sponsored by Charu Aggarwal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05853887 being conducted?
This trial has 6 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non Small Cell Lung Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RECRUITING · Phase 3
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Non Small Cell Lung Cancer Metastatic
All registered trials for this condition
Newly Diagnosed NSCLC
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.